| Type | Title | Date Released | |
|---|---|---|---|
10-Q | Form 10-Q | ||
8-K | Anika Reports Third Quarter 2026 Financial Results with 10% Revenue Growth and Raised Guidance | ||
144 | Form 144 | ||
4 | Fischetti Gary P (Reporting) | ||
SCHEDULE 13G/A | VANGUARD CAPITAL MANAGEMENT LLC (Filed by) | ||
S-8 | Form S-8 | ||
10-Q | Form 10-Q | ||
8-K | Anika Therapeutics Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance | ||
SCHEDULE 13G/A | BlackRock Portfolio Management LLC (Filed by) | ||
8-K | Anika Therapeutics, Inc. Enters into Fifth Amendment to Credit Agreement | ||
4 | Fischetti Gary P (Reporting) | ||
4 | HENNEMAN JOHN B III (Reporting) |
